Insys Therapeutics Inc., of Phoenix, entered a $225 million settlement to resolve separate criminal and civil investigations into its marketing of Subsys, a sublingual fentanyl spray approved by the FDA in 2012 for the treatment of breakthrough pain in cancer patients.